Company Filing History:
Years Active: 2024
Title: Praveen Singh: Innovator in HIV Therapeutics
Introduction
Praveen Singh is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly in the development of specific binding molecules for HIV treatment. His innovative work has the potential to improve the lives of individuals infected with HIV.
Latest Patents
Praveen Singh holds a patent for HIV specific binding molecules. This patent includes specific binding molecules, such as T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL derived from the HIV Gag gene product, p17. The TCRs in this invention feature non-natural mutations within the alpha and/or beta variable domains compared to a native TCR. These specific binding molecules exhibit improved stability and yield while retaining the advantageous properties of their native counterparts. They are particularly useful in developing soluble immunotherapeutic reagents for treating HIV-infected individuals.
Career Highlights
Praveen Singh is associated with Immunocore Limited, a company focused on innovative immunotherapy solutions. His work at Immunocore has positioned him as a key player in the field of HIV research and treatment.
Collaborations
Praveen collaborates with talented individuals such as Marcin Dembek and Luis Filipe Da Silva Godinho. These collaborations enhance the research and development efforts at Immunocore Limited.
Conclusion
Praveen Singh's contributions to HIV therapeutics through his innovative patents and collaborations highlight his importance in the field of immunotherapy. His work continues to pave the way for advancements in treatment options for HIV-infected individuals.